Twist Bioscience Corp

For the period ended Mar 31, 2024. Filed May 2, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 2, 2024

TWST$132.13-2.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of December 31, 2023	57,779	$—		$1,666,797		$(565)		$(1,076,190)	$590,042
Vesting of restricted stock units	229	$—		$—		$—		$—	$—
Exercise of stock options	69	—	1,317		—	—	1,317
Issuance of shares under the employee stock purchase program	124	—	2,047		—	—	2,047
Repurchases of common stock for income tax withholding	(39)	—	(1,535)		—	—	(1,535)
Stock-based compensation	—	—	13,847		—	—	13,847
Other comprehensive income	—	—	—		(95)	—	(95)
Net loss	—	—	—		—	(45,492)	(45,492)
Balances as of March 31, 2024	58,162	$—		$1,682,473		$(660)		$(1,121,682)	$560,131

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveincome · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of December 31, 2022	56,645	$—		$1,617,174		$(609)		$(870,240)	$746,325
Vesting of restricted stock units	198	$—		$—		$—		$—	$—
Exercise of stock options	22	—	250		—	—	250
Issuance of shares under the employee stock purchase program	132	—	2,537		—	—	2,537
Repurchases of common stock for income tax withholding	(64)	—	(1,262)		—	—	(1,262)
Issuance of shares from business acquisition	172	—	4,092		—	—	4,092
Stock-based compensation	—	—	10,426		—	—	10,426
Other comprehensive income	—	—	—		720	—	720
Net loss	—	—	—		—	(59,156)	(59,156)
Balances as of March 31, 2023	57,105	$—		$1,633,217		$111		$(929,396)	$703,932

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of September 30, 2023	57,557	$—		$1,657,222		$(756)		$(1,033,034)	$623,432
Impact of ASU 2016-13 adoption (Note 2)	—	$—		$—		$—		$(148)	$(148)
Vesting of restricted stock units	489	—	—		—	—	—
Exercise of stock options	127	—	2,268		—	—	2,268
Issuance of shares under the employee stock purchase program	124	—	2,047		—	—	2,047
Repurchases of common stock for income tax withholding	(135)	—	(3,960)		—	—	(3,960)
Stock-based compensation	—	—	24,896		—	—	24,896
Other comprehensive income	—	—	—		96	—	96
Net loss	—	—	—		—	(88,500)	(88,500)
Balances as of March 31, 2024	58,162	$—		$1,682,473		$(660)		$(1,121,682)	$560,131

Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveincome · Accumulateddeficit · Totalstockholders'equity
(In thousands) · Shares · Amount
Balances as of September 30, 2022	56,523	$—		$1,619,644		$(1,843)		$(828,416)	$789,385
Vesting of restricted stock units	322	$—		$—		$—		$—	$—
Exercise of stock options	58	—	853		—	—	853
Issuance of shares under the employee stock purchase plan	132	—	2,537		—	—	2,537
Repurchases of common stock for income tax withholding	(102)	—	(2,261)		—	—	(2,261)
Issuance of shares from business acquisition	172		4,092				4,092
Stock-based compensation	—	—	8,352		—	—	8,352
Other comprehensive income	—	—	—		1,954	—	1,954
Net loss	—	—	—		—	(100,980)	(100,980)
Balances as of March 31, 2023	57,105	$—		$1,633,217		$111		$(929,396)	$703,932

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.